Neurocrine Biosciences, Inc.
TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS

Abstract:

Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+).alpha.-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H- -pyrido[2,1-a]isoquinolin-2-ol ((+).alpha.-HTBZ) is used in the methods described herein for treating a subject in need thereof.